Received: 21 May 2021
Accepted: 28 July 2021
First Online: 21 August 2021
: This study was approved by an Institutional Review Board (Comité d’Éthique de la Société de Réanimation de Langue Française #CE-SRLF 19-55), according to the French regulation on non-interventional studies, which waived the need for signed informed consent for patients included in this database. No data allowing identification of the patients included in the study were recorded. The study was conducted in accordance with the Declaration of Helsinki principles.
: Pr Azoulay has received fees for lectures from MSD, Pfizer, and Alexion; his institution and research group have received support from Baxter, Jazz Pharmaceuticals, Fisher & Paykel, Gilead, Alexion, and Ablynx; and he received support for article research from Assistance Publique-Hôpitaux de Paris. Pr. Zafrani’s institution received funding from the Assistance Publique Hôpitaux de Paris, Jazz Pharmaceuticals. Pr Saliba has received honorarium/research fundings/grants from Novartis, Astellas, Chiesi, Gilead, Baxter and Neovii. Dr Gornet has served as a speaker for Amgen, Janssen Cilag, Sanofi, Takeda and Tillots Pharma. The remaining authors have disclosed that they do not have any potential conflicts of interest.